PetMed Express confirms revised $3 takeover bid from SilverCape
PetMed Express has confirmed that its board received a second unsolicited, non-binding and conditional acquisition proposal from SilverCape Investments Limited, this time at $3.00 per share in cash. The revised offer represents a step down from SilverCape's earlier approach of $4.00 per share, made in December 2025.
The Delray Beach, Florida-based online pet pharmacy said its board, with financial and legal advisers in tow, will evaluate the proposal in line with its fiduciary duties. Shareholders are not required to take any action at this stage.
A troubled process
The backstory is complicated. Following the December 2025 approach, PetMeds' board instructed its financial adviser to run a broad outreach process, contacting both strategic and financial parties that might have an acquisition interest. SilverCape was invited to participate on the same terms as all other potential bidders, including signing a nondisclosure agreement with a standard standstill provision.
After months of negotiation on the agreement, SilverCape told PetMeds' adviser in April 2026 that it was unwilling to execute an NDA containing a standstill clause. The company had by that point prepared extensive diligence materials and a formal management presentation. The board has now said it remains willing to engage with SilverCape on its latest proposal, but only upon execution of a customary NDA with a standstill provision.
No transaction is certain, and PetMeds stated it does not intend to comment further unless the board completes its review or determines that additional disclosure is required.
Market context
The lowered bid price will raise questions for PetMeds shareholders about whether SilverCape's revised proposal reflects deteriorating fundamentals at the company or simply a harder-nosed negotiating posture. The company trades on Nasdaq under the ticker PETS and operates as a direct-to-consumer veterinary pharmacy across all 50 US states, with offerings spanning branded and generic prescription drugs, compounded medications, and over-the-counter supplements through its PetMeds and PetCareRx brands.
The online pet pharmacy sector has faced sustained pressure since the pandemic-era boom years, with consumers returning to bricks-and-mortar veterinary practices and competition from large retail and e-commerce players intensifying. PetMeds competes in a space that includes well-capitalised rivals with broader pet-care ecosystems, meaning the strategic rationale for a financial buyer would likely centre on cost restructuring or a roll-up into a larger pet-health platform.
The fact that SilverCape's second offer is 25 per cent below its first is unusual and could signal either a reassessment of PetMeds' earnings trajectory or a calculated move to pressure the board. Shareholders and market observers will watch whether the board's formal sale process, which failed to secure NDA compliance from SilverCape, attracts any competing interest before the board responds formally to the current proposal.